metricas
covid
Medicina Clínica (English Edition) Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatme...
Journal Information

Statistics

Follow this link to access the full text of the article

Letter to the Editor
Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia”
Respuesta a: “Efectividad de alirocumab y evolocumab (PCSK9i) en el tratamiento de la hipercolesterolemia”
Montserrat Boscha,b,c, Elena Ballarína,c, Immaculada Danésa,b,c,
Corresponding author
immaculada.danes@vallhebron.cat

Corresponding author.
a Clinical Pharmacology Department, Vall d’Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
b Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Clinical Pharmacology Research Group, Vall d’Hebron Institut De Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
Read
Not available
Times
was read the article
Total PDF
Total HTML
Share statistics
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day

Follow this link to access the full text of the article